Home
    Disclaimer
    ← Back to 2-TFMXP

    2-TFMXP Stats & Data

    Dissociative Research-chemical
    2-tfm-mxp
    Psychoactive Class Dissociative
    Half-Life Estimated 4–8 h (no formal human PK; inference from MXP/diphenidine user reports and duration)

    Effect Profile

    Curated
    Dissociative 6.0

    Strong dissociative depth and motor impairment with mild mania, low insight

    Dissociative Depth×3
    10
    Mania / Compulsion×1
    4
    Insight / Novel Thought×2
    3
    Motor / Sensory Impairment×1
    10
    Based on reports from:
    Erowid Experience Reports PsychonautWiki 2-TFMXP

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Estimated 4–8 h (no formal human PK; inference from MXP/diphenidine user reports and duration)
    Addiction Potential
    Moderate. Like other diarylethylamine dissociatives, tolerance accrues quickly and the combination of stimulation with amnestic dissociation promotes compulsive redosing and binge patterns in some users. Urinary tract complications have been reported with chronic dissociative use more broadly.

    Tolerance Decay

    Full tolerance 3d Half tolerance 14d Baseline ~28d

    Acute tolerance builds rapidly over hours to days, similar to other NMDA antagonists. After multi‑day use, a partial tolerance can persist for 1–2 weeks and typically returns near baseline by 4–6 weeks if abstinent. Data are from class analogs and user reports rather than formal studies.

    Cross-Tolerances

    Ketamine
    60% ●○○
    MXP (methoxphenidine)
    80% ●●○
    3‑MeO‑PCP/O‑PCE (arylcyclohexylamines)
    50% ●○○
    DXM
    40% ●○○

    Harm Reduction

    drugs.wiki

    • 2‑TFMXP is the 2‑trifluoromethyl analogue of methoxphenidine (MXP). Formal human pharmacology is minimal; all dosing is extrapolated from user reports and structure–activity trends for diarylethylamines.

    • Compared with MXP, users often describe higher potency (roughly 1.5–2×) and more stimulation/mania‑proneness. Start low, allow a full onset, and avoid rapid redosing to reduce blackout risk.

    • Marked inter‑individual variability: a minority report minimal effects below 30 mg while others reach strong dissociation near 25 mg.

    • Visuals are typically lighter than PCP‑class drugs; disequilibrium, tinnitus, time‑dilation, and numbness are common.

    • Binge use can produce prolonged vertigo, amnesia, and after‑effects lasting into the next day; dissociative‑induced psychosis/mania has been repeatedly documented with related arylcyclohexylamines after multi‑day use.

    • Reagent tests may be weak/ambiguous for diarylethylamines; send to a drug‑checking lab when possible. Marquis often orange for diphenidine analogs; Mecke light/weak yellow.

    • Insufflation is harsh and inflames nasal mucosa; oral/sublingual ROA is generally less damaging.

    • Chronic dissociative exposure is linked to ulcerative cystitis and lower urinary tract dysfunction; spacing doses (days to weeks) and ceasing at early urinary symptoms (urgency, pain, blood) is prudent.

    • Do not drive or operate machinery until at least the following day; residual disequilibrium and cognitive effects can persist through the next 12–24 hours.

    • No validated spot‑test for 2‑TFMXP specifically; colors may be faint or atypical. Prefer accredited lab testing when available.

    References

    Drugs.wiki References

    ← Back to 2-TFMXP